[go: up one dir, main page]

MX2016014189A - Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico. - Google Patents

Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.

Info

Publication number
MX2016014189A
MX2016014189A MX2016014189A MX2016014189A MX2016014189A MX 2016014189 A MX2016014189 A MX 2016014189A MX 2016014189 A MX2016014189 A MX 2016014189A MX 2016014189 A MX2016014189 A MX 2016014189A MX 2016014189 A MX2016014189 A MX 2016014189A
Authority
MX
Mexico
Prior art keywords
small cell
cell lung
ctla
antibodies
treating non
Prior art date
Application number
MX2016014189A
Other languages
English (en)
Other versions
MX373019B (es
Inventor
Narwal Rajesh
Robbins Paul
Karakunnel Joyson
M Dar Mohammed
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2016014189A publication Critical patent/MX2016014189A/es
Publication of MX373019B publication Critical patent/MX373019B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se proporcionan métodos para tratar cánceres de pulmón no microcíticos que comprenden administrar una cantidad eficaz de MEDI4736 o un fragmento de unión a antígeno del mismo y tremelimumab o un fragmento de unión a antígeno del mismo.
MX2016014189A 2014-05-13 2015-05-12 Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antígeno 4 de linfocito t citotóxico (anti-ctla-4). MX373019B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461992658P 2014-05-13 2014-05-13
US201562105992P 2015-01-21 2015-01-21
US201562114336P 2015-02-10 2015-02-10
PCT/EP2015/060523 WO2015173267A1 (en) 2014-05-13 2015-05-12 Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer

Publications (2)

Publication Number Publication Date
MX2016014189A true MX2016014189A (es) 2017-05-04
MX373019B MX373019B (es) 2020-03-31

Family

ID=53175516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014189A MX373019B (es) 2014-05-13 2015-05-12 Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antígeno 4 de linfocito t citotóxico (anti-ctla-4).

Country Status (27)

Country Link
US (3) US10232040B2 (es)
EP (2) EP3603748A1 (es)
JP (4) JP6648038B2 (es)
KR (4) KR102333658B1 (es)
CN (2) CN113230398B (es)
AU (4) AU2015260962B2 (es)
BR (1) BR122023025321A2 (es)
CA (1) CA2947471A1 (es)
CY (1) CY1122642T1 (es)
DK (1) DK3142751T3 (es)
ES (1) ES2749098T3 (es)
GB (1) GB2531094A (es)
HR (1) HRP20191449T1 (es)
HU (1) HUE045965T2 (es)
IL (2) IL248528B (es)
LT (1) LT3142751T (es)
ME (1) ME03493B (es)
MX (1) MX373019B (es)
PL (1) PL3142751T3 (es)
PT (1) PT3142751T (es)
RS (1) RS59134B1 (es)
RU (1) RU2702332C2 (es)
SG (2) SG10201810108PA (es)
SI (1) SI3142751T1 (es)
SM (1) SMT201900544T1 (es)
TW (3) TWI780994B (es)
WO (1) WO2015173267A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210143932A (ko) 2013-09-11 2021-11-29 메디뮨 리미티드 종양 치료용 항-ｂ7-ｈ1 항체
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102333658B1 (ko) * 2014-05-13 2021-12-01 메디뮨 리미티드 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
GB2535256A (en) * 2014-08-28 2016-08-17 Medimmune Ltd Combination therapy for PD-L1 negative tumors
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding antibodies against PDL1 and methods for their preparation
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
JP7241352B2 (ja) * 2016-05-17 2023-03-17 ジーンセントリック セラピューティクス， インコーポレイテッド 肺扁平上皮癌のサブタイピングのための方法
JP7241353B2 (ja) * 2016-05-17 2023-03-17 ジーンセントリック セラピューティクス， インコーポレイテッド 肺腺癌のサブタイピングのための方法
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
KR102486057B1 (ko) * 2016-09-06 2023-01-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110944663A (zh) * 2016-11-11 2020-03-31 免疫医疗有限责任公司 用于治疗非小细胞肺癌的抗pd-l1和抗ctla-4抗体
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EA201991870A1 (ru) * 2017-02-16 2020-02-12 МЕДИММЬЮН, ЭлЭлСи Лечение рака мочевого пузыря с помощью антитела к pd-l1
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
AU2018412532B2 (en) * 2018-03-08 2025-05-08 Astrazeneca Ab Compositions and methods for treating late stage lung cancer
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP7487558B2 (ja) 2020-05-25 2024-05-21 船井電機株式会社 面光源装置および表示装置
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023077069A1 (en) * 2021-10-29 2023-05-04 OncoC4, Inc. Anti-ctla-4 antibody dosing regimens
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
AU2023401158A1 (en) 2022-12-01 2025-05-29 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
IL322179A (en) 2023-01-30 2025-09-01 Kymab Ltd Antibodies
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7158164B2 (en) 2003-08-29 2007-01-02 Fuji Photo Film Co., Ltd. Thermal development method and apparatus
AU2011203119C1 (en) 2005-05-09 2018-06-14 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN101248089A (zh) * 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
WO2008100562A2 (en) 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
SI3279215T1 (sl) 2009-11-24 2020-07-31 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
CN102000947B (zh) * 2010-10-14 2012-06-06 沈阳飞机工业（集团）有限公司 两半轴瓦的铣切加工方法
PT3111954T (pt) 2010-11-05 2019-07-10 Novartis Ag Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17
CN101975831B (zh) * 2010-11-25 2012-09-05 中国检验检疫科学研究院 高效液相色谱法测定化妆品中苯酚磺酸锌的方法
CN107519486B (zh) * 2011-06-24 2021-06-11 台北荣民总医院 于感染性与恶性疾病的治疗中提升免疫反应的方法
WO2013169388A1 (en) 2012-05-08 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarkers for ctla-4 blockade therapy and for pd-1 blockade therapy
WO2013172926A1 (en) * 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
CA2873402C (en) * 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
ES2819573T3 (es) * 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
JP6514647B2 (ja) * 2013-03-01 2019-05-15 アステックス ファーマシューティカルズ インコーポレイテッド 薬物組み合わせ
KR102333658B1 (ko) * 2014-05-13 2021-12-01 메디뮨 리미티드 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
HUE054339T2 (hu) * 2014-11-10 2021-08-30 Medimmune Ltd CD73-ra specifikus kötõmolekulák és alkalmazásaik
KR102740444B1 (ko) * 2015-04-17 2024-12-10 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
EA201991870A1 (ru) * 2017-02-16 2020-02-12 МЕДИММЬЮН, ЭлЭлСи Лечение рака мочевого пузыря с помощью антитела к pd-l1
US12042527B2 (en) * 2019-01-08 2024-07-23 Modernatx, Inc. Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers

Also Published As

Publication number Publication date
IL276481B (en) 2022-06-01
TW202123967A (zh) 2021-07-01
CN113230398B (zh) 2025-01-03
AU2015260962A1 (en) 2016-11-24
US10232040B2 (en) 2019-03-19
IL248528B (en) 2020-08-31
US20150328311A1 (en) 2015-11-19
JP2021098734A (ja) 2021-07-01
AU2020230309A1 (en) 2020-10-01
TWI707692B (zh) 2020-10-21
US20230115328A1 (en) 2023-04-13
HUE045965T2 (hu) 2020-01-28
US11446377B2 (en) 2022-09-20
AU2025202908A1 (en) 2025-05-15
RU2019129614A3 (es) 2021-12-27
JP2020090509A (ja) 2020-06-11
RU2016148645A (ru) 2018-06-19
JP6648038B2 (ja) 2020-02-14
PT3142751T (pt) 2019-10-25
GB201508097D0 (en) 2015-06-24
RU2016148645A3 (es) 2018-12-21
TWI780994B (zh) 2022-10-11
CN106456756A (zh) 2017-02-22
RU2019129614A (ru) 2020-07-16
AU2015260962B2 (en) 2020-06-11
WO2015173267A1 (en) 2015-11-19
JP7519477B2 (ja) 2024-07-19
CA2947471A1 (en) 2015-11-19
IL276481A (en) 2020-09-30
EP3142751B1 (en) 2019-08-07
ES2749098T3 (es) 2020-03-19
HRP20191449T1 (hr) 2019-11-15
IL248528A0 (en) 2016-12-29
JP2017520520A (ja) 2017-07-27
CN106456756B (zh) 2021-04-23
KR20170003575A (ko) 2017-01-09
KR20220162844A (ko) 2022-12-08
US20190240324A1 (en) 2019-08-08
AU2023204286B2 (en) 2025-02-06
CN113230398A (zh) 2021-08-10
CY1122642T1 (el) 2021-03-12
SI3142751T1 (sl) 2019-09-30
ME03493B (me) 2020-01-20
DK3142751T3 (da) 2019-10-14
KR102333658B1 (ko) 2021-12-01
TW202233239A (zh) 2022-09-01
KR20210149870A (ko) 2021-12-09
GB2531094A (en) 2016-04-13
SMT201900544T1 (it) 2019-11-13
SG11201609285SA (en) 2016-12-29
JP2023052607A (ja) 2023-04-11
SG10201810108PA (en) 2018-12-28
BR112016026197A2 (pt) 2018-02-20
BR122023025321A2 (pt) 2024-02-20
EP3142751A1 (en) 2017-03-22
RS59134B1 (sr) 2019-09-30
PL3142751T3 (pl) 2019-12-31
AU2020230309B2 (en) 2023-04-20
TW201545759A (zh) 2015-12-16
EP3603748A1 (en) 2020-02-05
MX373019B (es) 2020-03-31
LT3142751T (lt) 2019-09-25
AU2023204286A1 (en) 2023-07-27
KR20230165876A (ko) 2023-12-05
RU2702332C2 (ru) 2019-10-08

Similar Documents

Publication Publication Date Title
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
ZA201904316B (en) Methods of treating cancer with anti-pd-1 antibodies
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2016005801A (es) Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk.
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
GEAP202114453A (en) Anti-lag3 antibodies and antigen-binding fragments
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX382549B (es) Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
CR20170529A (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
PH12017501879A1 (en) Methods for treating cancer
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2017012553A (es) Compuestos espirociclicos.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
EP3134549A4 (en) Methods and materials for identifying and treating mammals having her2-positive breast cancer
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей

Legal Events

Date Code Title Description
FG Grant or registration